Feed

Herein, we report a case of nephrotic syndrome developed during chemotherapy with an anti-EGFR antibody. The patient was a 72-year-old man. He underwent surgery for sigmoid colon cancer and liver metastasis. Two months later, lung and lymph node metastases were observed, and CAPOX+anti-VEGF antibody therapy was initiated. The patient was switched to CPT-11+panitumumab due to disease progression. After 3 courses, he was diagnosed with nephrotic syndrome due to rapid weight gain with diuretic resistance, lower leg edema, and severe proteinuria. Chemotherapy was suspended, and the diuretic dose was increased. Four weeks later, laboratory data and symptoms improved, and chemotherapy with CPT-11 alone was resumed. The nephrotic syndrome did not recur. Therefore, its previous development was attributed to panitumumab treatment.